

Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE)

NCT06916520

Status	RECRUITING
Phase	Phase 4
Sponsor	J.P.S Henriques
Enrollment	300 participants

Key Eligibility Criteria

Inclusion (3)

- Acute Coronary Syndrome
- Chronic Coronary Syndrome
- Successful PCI

Exclusion (6)

- Known allergy or contraindication for prasugrel, including Active pathological bleeding Severe liver disease (defined as Child Pugh class C)
- Current indication for oral anticoagulant therapy (OAC)
- Indication for ongoing DAPT (e.g. PCI d 6 months for CCS or ACS d 12 months)
- Pregnancy or breast-feeding women
- Participation in another trial with an investigational drug or device
- ... and 1 more (see full listing online)

Locations (1 total)

Amsterdam UMC, Amsterdam, Netherlands